Article
Geldanamycin-Derived HSP90 Inhibitors Are Synthetic Lethal with NRF2.
Molecular and cellular biology - 26 Oct 2020
Baird Liam, Suzuki Takafumi, Takahashi Yushi, Hishinuma Eiji, Saigusa Daisuke, Yamamoto Masayuki
Abstract excerpt
Activating mutations in KEAP1-NRF2 are frequently found in tumors of the lung, esophagus, and liver, where they are associated with aggressive growth, resistance to cancer therapies, and low overall survival. Despite the fact that NRF2 is a validated driver of tumorigenesis and chemotherapeutic resistance, there are currently no approved drugs which can inhibit its activity. Therefore, there is an urgent clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.